Contact this trialFirst, we need to learn more about you.
Radioimmunotherapy
211^At-BC8-B10 for Acute Lymphoblastic Leukemia
Recruiting1 awardPhase 1 & 2
Seattle, Washington
This trial gives cancer patients astatine-211, a radioactive substance, before their donor stem cell transplant. The hope is that the astatine will kill the cancer cells while having less of an effect on the healthy cells.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.